Amp Capital Investors LTD Bei Gene, Ltd. Transaction History

Amp Capital Investors LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $473,506 - $741,692	-1,905 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $106,579 - $172,140	-427 Reduced 18.31%	1,905 $692,000
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $998,993 - $1.43 Million	-4,514 Reduced 65.94%	2,332 $595,000
Q3 2020 Nov 12, 2020	BUY	$189.18 - $286.44 $41,241 - $62,443	218 Added 3.29%	6,846 $1.93 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $199,850 - $315,196	-1,613 Reduced 19.57%	6,628 $1.26 Million
Q4 2019 Feb 13, 2020	SELL	$115.78 - $208.34 $11,809 - $21,250	-102 Reduced 1.22%	8,241 $1.37 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $260,011 - $334,987	2,281 Added 37.63%	8,343 $1.05 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $14,124 - $17,460	-115 Reduced 1.86%	6,062 $767,000
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $661,000 - $1.08 Million	6,177 New	6,177 $846,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Amp Capital Investors LTD, based on Form 13F filings with the SEC.

Stay updated on Amp Capital Investors LTD with notifications on news.